SHTG primary submission process

Size: px
Start display at page:

Download "SHTG primary submission process"

Transcription

1 Meeting date: 24 April 2014 Agenda item: 8 Paper number: SHTG Title: Purpose: SHTG primary submission process FOR INFORMATION Background The purpose of this paper is to update SHTG members on developments surrounding SHTG s Primary Submission Process (PSP). Action required SHTG is asked to note the continuing progress and provide feedback on the first draft of the submission template.

2 Situation The purpose of this paper is to update SHTG members on developments surrounding SHTG s Primary Submission Process (PSP). In recent weeks, progress has been made in; a) establishing the necessary information required for inclusion within PSP submission templates, and b) identifying potential topics for assessment during the pilot phase. Background In December 2013, SHTG endorsed the PSP subgroups proposals for the PSP pilot process. The proposals covered the following key phases of the pilot process; registration of technology for assessment with the Health Innovation Portal, onward referral to the PSP, assessment of the submission, and summary and dissemination of subsequent SHTG advice. It was agreed by SHTG that the next stage would be to develop more detailed PSP documentation, and to identify potential topics/devices for testing the process during the pilot. Assessment A draft manufacturer submission template is provided in Appendix 1 for consideration by SHTG. The template is at an early stage of development, and has been created based on work we have undertaken in collaboration with EUnetHTA, and also after having met with manufacturers of devices that may be suitable for assessment during the PSP pilot period. Ultimately, a guidance document for manufacturers will be provided alongside the submission template, yet the next stage is to establish whether the content of template is suitably comprehensive without being onerous. It is hoped that feedback from stakeholders and also from manufacturers who go through the imminent pilot process will help to fine-tune the content of the submission template. An update on the aforementioned work streams that have contributed to the development of the draft template is provided as follows; EUnetHTA is a network of government appointed organisations that produce or contribute to health technology assessment (HTA) in Europe, established to create an effective and sustainable network for HTA across Europe. We are currently working in collaboration with EUnetHTA on their Work Package 7 (WP7) programme, the objectives of which are; Strand A - to support the collaboration on new technologies and to contribute to reducing duplication of work by exchanging information on and developing tools to facilitate evidence generation, and Strand B - to exchange information on current assessments of new health technologies. The completion of these objectives will enable the creation of a comprehensive EUnetHTA submission template for medical devices. Healthcare Improvement Scotland (HIS) are partners of WP7 and have carried out data collection and synthesis in relation to Strand A and Strand B. This has involved, amongst other things, assessing and comparing the medical device templates used by HTA bodies in other countries. These comparisons were then used to help develop the draft EUnetHTA submission template where, most recently, HIS have been contributing to the amendment of the template. In addition to the above, we have been working closely with Scottish Lifesciences Association colleagues to identify medical devices that may be suitable for assessment during the PSP pilot phase. So far, we have met with the manufacturers of five different devices, across a broad spectrum of healthcare solutions from haemoglobin sprays to specialist catheters for use during heart transplants. We have presented our proposed PSP File Name: SHTG primary submission process Version: 1.0 Date: 30 September 2014 Produced by: Secretariat Page: 2 Review date: n/a

3 process to the manufacturers and common across all these meetings was the enthusiasm with which our proposed PSP has been met. This has been particularly reassuring and has highlighted the important role we have to play in the link between the medical device industry and the use of their products within NHSScotland. A key distinction between the various devices is their stage of development, ranging from prototypes to those that are already used within other European countries. Owing to the embryonic stage of our PSP process, this represents a welcome distinction which may help to ensure that we are able to manage our workload effectively. Recommendation SHTG is asked to note the continuing progress and provide feedback on the first draft of the submission template. Produced by: Secretariat Page: 3 Review date: n/a

4 APPENDIX 1 Draft PSP submission template for manufacturers Please complete all sections of the template. The text in italics is intended to help illustrate the required information under each heading. Completed forms to be returned to: TBC 1. Health problem and use of the technology Description of disease or health condition for which technology will be used Provide an overview of the disease or health condition for which the technology is being considered. Definition of the disease or health condition. Describe the known causes or risk factors for developing the disease or health condition. Describe the natural course of the disease or health condition, including reference to any prognosis factors that may affect this natural course. Effects of disease Describe the symptoms of the disease or health condition. Comment on the burden of disease and describe which aspects of the burden of disease are targeted by the technology, i.e. are expected to be improved by the use of the technology. Include an estimate of prevalence and/or incidence for the disease or health condition (including recent trends). Target population Define target population and provide a justification for the target population. Estimate size of target population (assuming different from overall prevalence/incidence figures for population). Please provide evidence for the estimates. File Name: SHTG primary submission process Version: 1.0 Date: 30 September 2014 Produced by: Secretariat Page: 4 Review date: n/a

5 Current clinical management of the disease or health condition Describe the clinical pathway of care that includes the proposed use of the technology. Describe the technologies currently used in the clinical pathway, for which the proposed technology is an alternative. Further detail surrounding comparator technologies is requested in Section 2. Describe any issues relating to current clinical practice, including any uncertainty about best practice. Describe the proposed new pathway of care which would incorporate the new technology if the technology was adopted by the NHS. Describe how the introduction of the new technology would impact upon the requirement for new resources, alternative use of existing resources, or a reduction in resource requirements (e.g. staff, tests/investigations, facilities etc.) 2. Description and use of the technology Manufacturer Name of applicant Manufacturer details (name, contact details, company number, legal status and whether a subsidiary) Sites where the device is manufactured Distributer details (to include name, contact details, company number, legal status and whether a subsidiary) Technology Name of device (full name in UK and, if different, in other countries worldwide) Class of the device Summarise the phase of development of the technology Provide details of the licence status of the technology detailed in the submission, including dates of granted or expected marketing approval. Where available, provide copies of relevant regulatory approval documents (e.g. CE mark certificate). Does the technology have regulatory approval outside Europe? If so, please provide details. Produced by: Secretariat Page: 5 Review date: n/a

6 Current use of technology and comparator(s) Use of the technology under review If the technology has been launched, please provide information on its use both in the UK and worldwide. List of supporting documents relating to the above: The brochure, model or presentation of the device (summary of characteristics) Letter of support for use of product, i.e. from clinicians, or evidence of use/approval in other countries If the technology has not been launched in the UK provide the anticipated date of availability in the UK. Use of comparator technologies If applicable, state the alternatives to the technology, for the indication(s) under assessment. Provide a justification for the choice of each of the comparators. Describe the variations in use of the comparators across countries/regions/settings, if any. 3. Clinical effectiveness Identification and selection of clinical effectiveness studies Present details of literature search used to identify studies to support clinical effectiveness evidence for the technology. Where possible; State the date of the search and any date limits applied Give details of the search strategy used and which databases were searched Present study inclusion and exclusion criteria If possible, please provide a flow chart showing the number of studies identified and excluded. The PRISMA template may be used: Produced by: Secretariat Page: 6 Review date: n/a

7 Details of clinical effectiveness studies Present details of all studies used as evidence. For each study identified please state the following (data may be presented in tables). 1. Study title 2. Study reference and references for linked publications (including author and dates) 3. Registration number and name of trial registry 4. Conflicts of interest 5. Dates of study 6. Study location 7. Study objective (s) 8. Study design (RCT, randomisation method, blinding etc. If study was not an RCT, include how participants were allocated) 9. Study population (method of recruitment, selection criteria, exclusion criteria) 10. Treatment plan (dose, method of administration, timing and duration of administration) 11. Comparator (if usual care, please describe what this constitutes) 12. Follow-up procedures 13. Main outcome measure (if this uses a scale, state how it was validated) 14. Secondary outcome measures 15. Methods of analysing the results Where the evidence (indirect comparison, meta-analysis etc.) has been carried out, please record the methods used to carry out the evidence synthesis. Please also present the key results from the evidence synthesis below. ( ns.pdf may provide further guidance useful for completing this section). Produced by: Secretariat Page: 7 Review date: n/a

8 Clinical effectiveness study results In addition to the above, for each study identified please present the key clinical effectiveness results that will be used to support the clinical effectiveness of the device. Consider the following details when presenting the results Main outcome measure - effect size (+ 95% CI), statistical test (+ p value) Secondary outcome measures - effect size (+ 95% CI), statistical test (+ p value) Ongoing and unpublished studies For each study please state the following information if available: Study description Study results Study quality if this is possible to assess. For on-going studies, publication date For unpublished studies: reasons for non-publication Generalisability and consistency of studies in relation to proposed clinical situation Provide a summary of the strengths and limitations of the clinical-evidence base of the technology. Consideration should be given to the following; General characteristics of study populations and geographic and clinical setting of studies, how these might differ from the proposed target population General characteristics of the interventions examined and how they compare to those in routine use. Comparators used. Describe whether they reflect the most appropriate comparators in clinical practice in Scotland. The outcome measures, and whether this represents a comprehensive list. Conclusions on clinical effectiveness Based on the information provided above, provide a concluding statement regarding the clinical effectiveness evidence highlighting the clinical benefit from the technology. Produced by: Secretariat Page: 8 Review date: n/a

9 4. Safety Identification and selection of safety studies For the technology under consideration, and the comparator(s), list any additional studies in this safety section which were not included in the clinical effectiveness section. In doing so, provide details of identification and selection of studies in the same way as presented for the clinical effectiveness studies. Results of the studies (safety-specific information) Present the safety outcomes in the clinical studies. Where possible, consideration should be given to the following; For the technology under consideration, the number (and %) of patients requiring permanent or temporary discontinuation of treatment for each study providing safety data. For the technology under consideration, and the comparator, present the total events, frequency of occurrence (as a %), relative risk and 95% CI reported in each of the clinical studies. Categorise the adverse events by frequency and severity, and system order class. Are there any patient subgroups that are more likely to be harmed through use of the technology? If so present the data for these groups, separately. Describe all adverse events and outcomes associated with the technology in national regulatory databases such as those maintained by the MHRA and FDA. Study quality and generalisability of safety results Provide information surrounding the quality and relevance of the safety outcomes presented. Consideration should be given to the following; Were definitions given of reported adverse effects? How were adverse effects data collected: prospective/routine monitoring, spontaneous reporting, patient checklist/ questionnaire/diary; systematic survey of patients? Did investigators report on all the likely important or serious adverse effects? Are the safety data relevant for clinical practice in NHS Scotland? Safety risk management Comment on whether there is a need to manage the use of the technology, or to monitor the use of the technology to minimise the potential risks to safety If relevant, describe any changes made to the marketing authorisation since the initial authorisation as a result of safety issues. Describe any other harms that have come to light after granting of the marketing authorisation or that have been identified outside of the clinical trial context. Produced by: Secretariat Page: 9 Review date: n/a

10 Conclusions on safety Based on the information provided above, provide a summary statement relating to the safety evidence surrounding the technology. Include the following; What are the most important risks? What are the main differences between the technology and the comparator(s)? Are any patient groups more likely to be at risk? Describe the factors that may affect safety outcomes, e.g. clinician training, patient behaviour etc. 5. Health economics Published economic literature Please provide details of published economic studies used to support the use of the technology. Consideration should be given to the information requirements set out in Section 3 surrounding the identification, selection, description and results of relevant studies. De novo economic evaluation The purpose of the PSP is to provide submitting manufacturers the opportunity to present their own economic evaluation surrounding the use of their technology. As such, please provide details of the economic analysis below under the following broad headings. Overview of the Economic Evaluation Provide a description of the design of the economic evaluation. Define the decision problem to be addressed. This will require a definition and justification of the technologies being compared and the relevant patient group(s). Type of Economic Evaluation Describe the type of economic evaluation (e.g. cost-effectiveness analysis, cost-utility analysis, costminimisation analysis, cost-consequence analysis, or cost-benefit analysis). Justify the choice of economic evaluation. Produced by: Secretariat Page: 10 Review date: n/a

11 Comparator used in the economic analysis The comparator(s) for the economic analysis is likely to be the same as specified within the previous sections of the template. Provide details of the comparator(s) within the economic analysis. Please note that relevant comparators for inclusion in the economic analysis are those that are considered to be in routine use or represent best practice in NHS Scotland, and therefore are the technologies that are most likely to be replaced if the technology under review is recommended for use. Perspective of economic analysis Describe the perspective of the economic analysis. The perspective on outcomes should be all direct health effects. The perspective adopted on costs should be that of the NHS in Scotland and social work. If the inclusion of a wider set of costs or outcomes is expected to influence the results significantly, reasons for their inclusion should be clearly stated. Time Horizon for the Economic Evaluation State the time horizon for estimating the relative cost-effectiveness of the technology. The time horizon should be sufficiently long to reflect any differences in costs or outcomes between the technologies being compared. Role of Expert Opinion Where data from studies are insufficient to provide values for relevant variables, and such values can be obtained from expert opinion, then expert opinion will be considered as a valid source of evidence. Provide details of the expert opinion garnered to support the economic evaluation. Consider the extent of the expert opinion in relation to both the relative clinical outcomes and the costs of the technology and the comparator. Relative outcomes All the relevant clinical literature relating to the technology under evaluation will have been included in the previous sections of the submission template. For use in the economic analysis, summarise the key clinical outcomes that will be used to inform the economic analysis. Where clinical trial data have been combined, for example where there is no head to head evidence between the technology under review and the comparator, described the methods used and the key findings. For example, where indirect comparisons, systematic reviews, or network meta analyses have been carried out. Produced by: Secretariat Page: 11 Review date: n/a

12 Relative costs Costs should relate to resources that are under the control of the NHS in Scotland and social work where differential effects on costs between the technologies under comparison are possible. Please provide details of the cost data included within the economic evaluation. Consideration should be given to the following; Technology costs including those of the relevant comparators. Costs of resources associated with the use of the technology (e.g. staff costs, consumables etc.) Source of cost data (including the evidence used to estimate quantity and value of resources used) Discounting Present the discount rate applied to outcomes and costs. Results of health economics Present the key results from the economic evaluation. Consideration should be given to the graphical representation of clinical and cost-effectiveness data to support its effective communication and interpretation. Present the results of any sensitivity analysis used to test areas of uncertainty. Summary of health economic evaluation Based on the information provided above, provide a summary statement relating to the health economic evidence surrounding the technology. 6. Conclusion Summary of submission In no more than 6 bullet points summarise the key points to support the use of the technology within NHS Scotland Produced by: Secretariat Page: 12 Review date: n/a

Issues in Emerging Health Technologies Bulletin Process

Issues in Emerging Health Technologies Bulletin Process Issues in Emerging Health Technologies Bulletin Process Updated: April 2015 Version 1.0 REVISION HISTORY Periodically, this document will be revised as part of ongoing process improvement activities. The

More information

Convergence and Differentiation within the Framework of European Scientific and Technical Cooperation on HTA

Convergence and Differentiation within the Framework of European Scientific and Technical Cooperation on HTA EUnetHTA European network for Health Technology Assessment Convergence and Differentiation within the Framework of European Scientific and Technical Cooperation on HTA University of Tokyo, October 24,

More information

European Network for Health Technology Assessment (EUnetHTA) Joint Action 3

European Network for Health Technology Assessment (EUnetHTA) Joint Action 3 European Network for Health Technology Assessment (EUnetHTA) Joint Action 3 Zoe Garrett, Senior Technical Adviser Lead WP7 National Implementation and Impact National Institute for Health and Care Excellence

More information

CADTH HEALTH TECHNOLOGY MANAGEMENT PROGRAM Horizon Scanning Products and Services Processes

CADTH HEALTH TECHNOLOGY MANAGEMENT PROGRAM Horizon Scanning Products and Services Processes CADTH HEALTH TECHNOLOGY MANAGEMENT PROGRAM Horizon Scanning Products and Services Processes Service Line: Health Technology Management Program Version: 1.0 Publication Date: September 2017 Report Length:

More information

December Eucomed HTA Position Paper UK support from ABHI

December Eucomed HTA Position Paper UK support from ABHI December 2008 Eucomed HTA Position Paper UK support from ABHI The Eucomed position paper on Health Technology Assessment presents the views of the Medical Devices Industry of the challenges of performing

More information

Andalusian Agency for Health Technology Assessment (AETSA)

Andalusian Agency for Health Technology Assessment (AETSA) Andalusian Agency for Health Technology Assessment (AETSA) Seville, 22 nd of July, 2016 Comments on the concept paper Facilitating the translation of advanced therapies to patients in Europe 1 Introduction

More information

NHS South Tees Clinical Commissioning Group. Governing Body. Agenda Item:

NHS South Tees Clinical Commissioning Group. Governing Body. Agenda Item: NHS South Tees Clinical Commissioning Group Governing Body Agenda Item: Wednesday, 18 th September 2013 Title Quarter 1 Assurance Report Responsible Officer Amanda Hume Author of the Report Craig Blair

More information

Reflection Paper on synergies between regulatory and HTA issues. DG SANTE Unit B4 Medical products: safety, quality, innovation

Reflection Paper on synergies between regulatory and HTA issues. DG SANTE Unit B4 Medical products: safety, quality, innovation Reflection Paper on synergies between regulatory and HTA issues DG SANTE Unit B4 Medical products: safety, quality, innovation STAMP meeting, 28 June 2016 Outline Aim of the Reflection Paper Drafting process

More information

25 th Workshop of the EURORDIS Round Table of Companies (ERTC)

25 th Workshop of the EURORDIS Round Table of Companies (ERTC) 25 th Workshop of the EURORDIS Round Table of Companies (ERTC) Healthcare Companies & European Reference Networks: Expectations & Potential for Collaboration Introduction Tuesday 26 September, 2017 (09:00

More information

TWO BY TWO: A METHODOLOGICAL PERSPECTIVE ON THE USE OF EVIDENCE TO SUPPORT THE VALUE OF A HEALTH TECHNOLOGY

TWO BY TWO: A METHODOLOGICAL PERSPECTIVE ON THE USE OF EVIDENCE TO SUPPORT THE VALUE OF A HEALTH TECHNOLOGY TWO BY TWO: A METHODOLOGICAL PERSPECTIVE ON THE USE OF EVIDENCE TO SUPPORT THE VALUE OF A HEALTH TECHNOLOGY A/Prof Tracy Merlin Adelaide Health Technology Assessment (AHTA) School of Population Health

More information

GOVERNING BODY MEETING in Public 25 April 2018 Agenda Item 3.2

GOVERNING BODY MEETING in Public 25 April 2018 Agenda Item 3.2 GOVERNING BODY MEETING in Public 25 April 2018 Paper Title Paper Author(s) Jerry Hawker Accountable Officer NHS Eastern Cheshire CCG The Future of CCG Commissioning in Cheshire Alison Lee Accountable Officer

More information

SURGERY STRATEGIC CLINICAL NETWORK EVIDENCE DECISION SUPPORT PROGRAM. New ideas & Improvements

SURGERY STRATEGIC CLINICAL NETWORK EVIDENCE DECISION SUPPORT PROGRAM. New ideas & Improvements SURGERY STRATEGIC CLINICAL NETWORK EVIDENCE DECISION SUPPORT PROGRAM 2014 Revision (v3) New ideas & Improvements Department of Surgery Evidence Decision Support Program Resource Tool Box Regional Clinical

More information

HTA Position Paper. The International Network of Agencies for Health Technology Assessment (INAHTA) defines HTA as:

HTA Position Paper. The International Network of Agencies for Health Technology Assessment (INAHTA) defines HTA as: HTA Position Paper The Global Medical Technology Alliance (GMTA) represents medical technology associations whose members supply over 85 percent of the medical devices and diagnostics purchased annually

More information

Extract of Advance copy of the Report of the International Conference on Chemicals Management on the work of its second session

Extract of Advance copy of the Report of the International Conference on Chemicals Management on the work of its second session Extract of Advance copy of the Report of the International Conference on Chemicals Management on the work of its second session Resolution II/4 on Emerging policy issues A Introduction Recognizing the

More information

Stage 2: eligibility screening. Stage 3: prioritisation. Stage 4: selection

Stage 2: eligibility screening. Stage 3: prioritisation. Stage 4: selection Digital therapy technology endorsement for IAPT project eligibility and prioritisation criteria NICE has been commissioned by NHS England to assess selected, digitally enabled therapies for depression

More information

Technology and Innovation in the NHS Highlands and Islands Enterprise

Technology and Innovation in the NHS Highlands and Islands Enterprise Technology and Innovation in the NHS Highlands and Islands Enterprise Introduction Highlands and Islands Enterprise (HIE) welcomes the opportunity to respond to the Committee s call for views. We recognise

More information

Committee on Development and Intellectual Property (CDIP)

Committee on Development and Intellectual Property (CDIP) E CDIP/16/4 REV. ORIGINAL: ENGLISH DATE: FERUARY 2, 2016 Committee on Development and Intellectual Property (CDIP) Sixteenth Session Geneva, November 9 to 13, 2015 PROJECT ON THE USE OF INFORMATION IN

More information

Committee on Development and Intellectual Property (CDIP)

Committee on Development and Intellectual Property (CDIP) E CDIP/6/4 REV. ORIGINAL: ENGLISH DATE: NOVEMBER 26, 2010 Committee on Development and Intellectual Property (CDIP) Sixth Session Geneva, November 22 to 26, 2010 PROJECT ON INTELLECTUAL PROPERTY AND TECHNOLOGY

More information

Reduce cost sharing and fees Include other services. Services: which services are covered? Population: who is covered?

Reduce cost sharing and fees Include other services. Services: which services are covered? Population: who is covered? 3.3 Assessment: National health technology assessment unit 3.3.1 Introduction Health systems throughout the world are struggling with the challenge of how to manage health care delivery in resource-constrained

More information

November 18, 2011 MEASURES TO IMPROVE THE OPERATIONS OF THE CLIMATE INVESTMENT FUNDS

November 18, 2011 MEASURES TO IMPROVE THE OPERATIONS OF THE CLIMATE INVESTMENT FUNDS November 18, 2011 MEASURES TO IMPROVE THE OPERATIONS OF THE CLIMATE INVESTMENT FUNDS Note: At the joint meeting of the CTF and SCF Trust Fund Committees held on November 3, 2011, the meeting reviewed the

More information

The NHS England Assurance Framework: national report for consultation Chief Officer, Barnet Clinical Commissioning Group

The NHS England Assurance Framework: national report for consultation Chief Officer, Barnet Clinical Commissioning Group Meeting Health and Well-Being Board Date 27 June 2013 Subject Report of Summary of item and decision being sought The NHS England Assurance Framework: national report for consultation Chief Officer, Barnet

More information

Health Based Exposure Limits (HBEL) and Q&As

Health Based Exposure Limits (HBEL) and Q&As Health Based Exposure Limits (HBEL) and Q&As The EMA guideline (EMA/CHMP/ CVMP/ SWP/169430/2012) & EMA/CHMP/CVMP/SWP/463311/2016 Graeme McKilligan, UK, MHRA. Content Intent of HBEL Post Implementation

More information

Health Technology Assessment of Medical Devices in Low and Middle Income countries: challenges and opportunities

Health Technology Assessment of Medical Devices in Low and Middle Income countries: challenges and opportunities Health Technology Assessment of Medical Devices in Low and Middle Income countries: challenges and opportunities Aleksandra Torbica, Carlo Federici, Rosanna Tarricone Centre for Research on Health and

More information

TGA Discussion Paper 3D Printing Technology in the Medical Device Field Australian Regulatory Considerations

TGA Discussion Paper 3D Printing Technology in the Medical Device Field Australian Regulatory Considerations TGA Discussion Paper 3D Printing Technology in the Medical Device Field Australian Regulatory Considerations MTAA Response - October 2017 October 2017 Australian Regulatory Considerations Page 1 of 7 Level

More information

13 December A NERA Briefing: Expert Workshop on HTA Workshop Sponsored by Pfizer

13 December A NERA Briefing: Expert Workshop on HTA Workshop Sponsored by Pfizer 13 December 2007 A NERA Briefing: Expert Workshop on HTA Workshop Sponsored by Pfizer Project Team Leela Barham Michelle Ng NERA Economic Consulting 15 Stratford Place London W1C 1BE United Kingdom Tel:

More information

Committee on Development and Intellectual Property (CDIP)

Committee on Development and Intellectual Property (CDIP) E CDIP/10/13 ORIGINAL: ENGLISH DATE: OCTOBER 5, 2012 Committee on Development and Intellectual Property (CDIP) Tenth Session Geneva, November 12 to 16, 2012 DEVELOPING TOOLS FOR ACCESS TO PATENT INFORMATION

More information

Herts Valleys Clinical Commissioning Group. Review of NHS Herts Valleys CCG Constitution

Herts Valleys Clinical Commissioning Group. Review of NHS Herts Valleys CCG Constitution Herts Valleys Clinical Commissioning Group Review of NHS Herts Valleys CCG s constitution Agenda Item: 14 REPORT TO: HVCCG Board DATE of MEETING: 30 January 2014 SUBJECT: Review of NHS Herts Valleys CCG

More information

International Civil Aviation Organization ASSEMBLY 38TH SESSION EXECUTIVE COMMITTEE

International Civil Aviation Organization ASSEMBLY 38TH SESSION EXECUTIVE COMMITTEE International Civil Aviation Organization WORKING PAPER 10/9/13 English only Agenda Item 13: Aviation Security Policy ASSEMBLY 38TH SESSION EXECUTIVE COMMITTEE INNOVATION IN SECURITY DEVELOPMENT OF NEXT

More information

learning progression diagrams

learning progression diagrams Technological literacy: implications for Teaching and learning learning progression diagrams The connections in these Learning Progression Diagrams show how learning progresses between the indicators within

More information

MedTech Europe position on future EU cooperation on Health Technology Assessment (21 March 2017)

MedTech Europe position on future EU cooperation on Health Technology Assessment (21 March 2017) MedTech Europe position on future EU cooperation on Health Technology Assessment (21 March 2017) Table of Contents Executive Summary...3 The need for healthcare reform...4 The medical technology industry

More information

ENCePP Work Plan

ENCePP Work Plan EMA/231507/2012 ENCePP Secretariat European Network of Centres for Pharmacoepidemiology and Pharmacovigilance European Network of Centres for Pharmacoepidemiology and Pharmacovigilance Adopted by the ENCePP

More information

Adaptation of HTA reports: an effective way to use limited resources?

Adaptation of HTA reports: an effective way to use limited resources? Adaptation of HTA reports: an effective way to use limited resources? Iñaki Gutiérrez-Ibarluzea, Osteba, Basque Office for HTA. Ministry for Health, Basque Government Introducing the Basque Country Basque

More information

Research Development Request - Profile Template. European Commission

Research Development Request - Profile Template. European Commission Research Development Request - Profile Template European Commission Research Development Request Profile The following table can be used as a template for drafting a Research Development Request profile.

More information

Medical Education Activities

Medical Education Activities Medical Education Activities Author: Marie-Claire PICKAERT EFPIA Deputy Director General BioMed Alliance Brussels, 9 November 2016 MCP 07-11--2016 Declaration of Interest Marie-Claire Pickaert is a full-time

More information

New methods, how could Norway speed up Health Technology Assessment (HTA) to the benefit of health industry, policy-makers, clinicians and patients?

New methods, how could Norway speed up Health Technology Assessment (HTA) to the benefit of health industry, policy-makers, clinicians and patients? New methods, how could Norway speed up Health Technology Assessment (HTA) to the benefit of health industry, policy-makers, clinicians and patients? Department director Øyvind Melien Reviews and HTA, Norwegian

More information

EU s Innovative Medical Technology and EMA s Measures

EU s Innovative Medical Technology and EMA s Measures EU s Innovative Medical Technology and EMA s Measures 27 October 2017 Summit symposium 25-27 October 2017, Kyoto, Japan Presented by Guido Rasi Executive Director, European Medicines Agency (EMA) An agency

More information

Committee on Development and Intellectual Property (CDIP)

Committee on Development and Intellectual Property (CDIP) E CDIP/16/4 ORIGINAL: ENGLISH DATE: AUGUST 26, 2015 Committee on Development and Intellectual Property (CDIP) Sixteenth Session Geneva, November 9 to 13, 2015 PROJECT ON THE USE OF INFORMATION IN THE PUBLIC

More information

Tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases

Tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases Tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases In 2017 the multi-stakeholder initiative was set up to: Facilitate a shared understanding of the

More information

EXPERT GROUP MEETING ON CONTEMPORARY PRACTICES IN CENSUS MAPPING AND USE OF GEOGRAPHICAL INFORMATION SYSTEMS New York, 29 May - 1 June 2007

EXPERT GROUP MEETING ON CONTEMPORARY PRACTICES IN CENSUS MAPPING AND USE OF GEOGRAPHICAL INFORMATION SYSTEMS New York, 29 May - 1 June 2007 EXPERT GROUP MEETING ON CONTEMPORARY PRACTICES IN CENSUS MAPPING AND USE OF GEOGRAPHICAL INFORMATION SYSTEMS New York, 29 May - 1 June 2007 STATEMENT OF DR. PAUL CHEUNG DIRECTOR OF THE UNITED NATIONS STATISTICS

More information

Parenteral Nutrition Down Under Inc. (PNDU) Working with Pharmaceutical Companies Policy (Policy)

Parenteral Nutrition Down Under Inc. (PNDU) Working with Pharmaceutical Companies Policy (Policy) Parenteral Nutrition Down Under Inc. (PNDU) Working with Pharmaceutical Companies Policy (Policy) BACKGROUND (Reason or Purpose) The purpose of this Policy is to provide clear principles and guidance about

More information

Health Technology Assessment: What are the key challenges to assess medical devices? Rosanna Tarricone, PhD Director CERGAS Scientific Director EHTI

Health Technology Assessment: What are the key challenges to assess medical devices? Rosanna Tarricone, PhD Director CERGAS Scientific Director EHTI Health Technology Assessment: What are the key challenges to assess medical devices? Rosanna Tarricone, PhD Director CERGAS Scientific Director EHTI SAMED, Annual Conference, May 29 th 2014 From «Does

More information

The EFPIA Perspective on the GDPR. Brendan Barnes, EFPIA 2 nd Nordic Real World Data Conference , Helsinki

The EFPIA Perspective on the GDPR. Brendan Barnes, EFPIA 2 nd Nordic Real World Data Conference , Helsinki The EFPIA Perspective on the GDPR Brendan Barnes, EFPIA 2 nd Nordic Real World Data Conference 26-27.9.2017, Helsinki 1 Key Benefits of Health Data Improved decision-making Patient self-management CPD

More information

ABHI Response to the Kennedy short study on Valuing Innovation

ABHI Response to the Kennedy short study on Valuing Innovation ABHI Response to the Kennedy short study on Valuing Innovation Introduction 1. The Association of British Healthcare Industries (ABHI) is the industry association for the UK medical technology sector.

More information

Vital Statistics from Civil Registration Records

Vital Statistics from Civil Registration Records Fourth Conference of African Ministers responsible for Civil Registration Experts meeting Nouakchott 4-8 December 2017 AUC/CRMC4/2017/9 Vital Statistics from Civil Registration Records Issue paper 17-01605

More information

Final Minutes of EMA/EUnetHTA meeting

Final Minutes of EMA/EUnetHTA meeting 4 June 2013 EMA/297283/2013 14 May 2013 chaired by Hans-Georg Eichler and Finn Børlum Kristensen Role Chairs Participants Name Hans-Georg Eichler and Finn Børlum Kristensen EMA: Peter Arlett, Michael Berntgen,

More information

EU Research Integrity Initiative

EU Research Integrity Initiative EU Research Integrity Initiative PROMOTING RESEARCH INTEGRITY IS A WIN-WIN POLICY Adherence to the highest level of integrity is in the interest of all the key actors of the research and innovation system:

More information

2. Evidence themes and their importance along the development path

2. Evidence themes and their importance along the development path 1. The issue On 12 th July 2017, MedCity, Digital Health.London and BSI hosted a Digital Health Technology and Evidence Stakeholder workshop. It brought together the key experts for the innovation development

More information

Project Status Update

Project Status Update Project Status Update Reporting cycle: 1 October 2016 to 30 June 2017 (Year 1) Date: 13 July 2017 Designated Charity: Funded initiative: Snapshot overview: headspace National Youth Mental Health Foundation

More information

Systems Approaches to Health and Wellbeing in the Changing Urban Environment

Systems Approaches to Health and Wellbeing in the Changing Urban Environment Systems Approaches to Health and Wellbeing in the Changing Urban Environment Call for expressions of interest to establish International Centres of Excellence (UHWB ICE) TERMS OF REFERENCE Co-sponsored

More information

Publishing date: 23/07/2015 Document title: We appreciate your feedback. Share this document

Publishing date: 23/07/2015 Document title: We appreciate your feedback. Share this document Publishing date: 23/07/2015 Document title: We appreciate your feedback Please click on the icon to take a 5 online survey and provide your feedback about this document Share this document REPORT ON UNIT

More information

PROPORTIONATE EIA The Arcadis Perspective. David Hoare 18 July 2017

PROPORTIONATE EIA The Arcadis Perspective. David Hoare 18 July 2017 PROPORTIONATE EIA The Arcadis Perspective David Hoare 18 July 2017 PROPORTIONATE SCOPING Effective and Proportionate? We tend to produce a scoping table which summarises the main issues, whether they are

More information

Portsmouth CCG. CCG 360 o stakeholder survey 2015 Main report. Version 1 Internal Use Only Version 1 Internal Use Only

Portsmouth CCG. CCG 360 o stakeholder survey 2015 Main report. Version 1 Internal Use Only Version 1 Internal Use Only CCG 360 o stakeholder survey 2015 Main report Version 1 Internal Use Only 1 Table of contents Slide 3 Background and objectives Slide 4 Methodology and technical details Slide 6 Interpreting the results

More information

I. Introduction. Cover note. A. Mandate. B. Scope of the note. Technology Executive Committee. Fifteenth meeting. Bonn, Germany, September 2017

I. Introduction. Cover note. A. Mandate. B. Scope of the note. Technology Executive Committee. Fifteenth meeting. Bonn, Germany, September 2017 Technology Executive Committee 31 August 2017 Fifteenth meeting Bonn, Germany, 12 15 September 2017 Draft TEC and CTCN inputs to the forty-seventh session of the Subsidiary Body for Scientific and Technological

More information

Health Technology Assessment and the European Network for HTA

Health Technology Assessment and the European Network for HTA Health Technology Assessment and the European Network for HTA www.eunethta.eu Marcial Velasco Garrido, Technische Universität Berlin for the European Network for HTA, EUnetHTA Outline What is Health Technology

More information

Trafford CCG. CCG authorisation 360 o stakeholder survey report. Version 18 Internal Use Only Version 14 Internal Use Only

Trafford CCG. CCG authorisation 360 o stakeholder survey report. Version 18 Internal Use Only Version 14 Internal Use Only Trafford CCG CCG authorisation 360 o stakeholder survey report Version 18 Internal Use Only 1 Background and objectives In April 2012 the NHS Commissioning Board Authority (NHSCBA) published Clinical commissioning

More information

IoT in Health and Social Care

IoT in Health and Social Care IoT in Health and Social Care Preserving Privacy: Good Practice Brief NOVEMBER 2017 Produced by Contents Introduction... 3 The DASH Project... 4 Why the Need for Guidelines?... 5 The Guidelines... 6 DASH

More information

Health & Social Care Industrial Innovation

Health & Social Care Industrial Innovation Health & Social Care Industrial Innovation Mr Andrew Fowlie Scottish Government Health Innovations Team SHINE North Sea Region Program 2014 2020 Scotland s Medical Technologies Landscape Imaging Non Imaging

More information

European Charter for Access to Research Infrastructures - DRAFT

European Charter for Access to Research Infrastructures - DRAFT 13 May 2014 European Charter for Access to Research Infrastructures PREAMBLE - DRAFT Research Infrastructures are at the heart of the knowledge triangle of research, education and innovation and therefore

More information

E5 Implementation Working Group Questions & Answers (R1) Current version dated June 2, 2006

E5 Implementation Working Group Questions & Answers (R1) Current version dated June 2, 2006 INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE E5 Implementation Working Group & (R1) Current version dated June 2, 2006 ICH Secretariat,

More information

An Essential Health and Biomedical R&D Treaty

An Essential Health and Biomedical R&D Treaty An Essential Health and Biomedical R&D Treaty Submission by Health Action International Global, Initiative for Health & Equity in Society, Knowledge Ecology International, Médecins Sans Frontières, Third

More information

Innosup Supporting Experimentation in Innovation Agencies

Innosup Supporting Experimentation in Innovation Agencies H2020 Programme 2018-2020 For a better innovation support to SMEs Innosup-06-2018-2020 Supporting Experimentation in Innovation Agencies Background Note to the Call Topic Version 1.0 17 January 2018 1.

More information

Sustainable prevention of obesity through integrated strategies

Sustainable prevention of obesity through integrated strategies Sustainable prevention of obesity through integrated strategies Periodic Project Report II for the SPOTLIGHT project Grant Agreement no: 278186 01/09/2013 28/02/2015 1 SPOTLIGHT: Sustainable prevention

More information

Development funding allocation

Development funding allocation IAPT assessment programme Section 1: background Development funding allocation Digitally-enabled therapy technologies that meet all of the eligibility requirements for this programme are prioritised by

More information

TOWARD TRANSPARENCY IN HEALTH TECHNOLOGY ASSESSMENT

TOWARD TRANSPARENCY IN HEALTH TECHNOLOGY ASSESSMENT International Journal of Technology Assessment in Health Care, 19:1 (2003), 1 7. Copyright c 2003 Cambridge University Press. Printed in the U.S.A. TOWARD TRANSPARENCY IN HEALTH TECHNOLOGY ASSESSMENT A

More information

SAUDI ARABIAN STANDARDS ORGANIZATION (SASO) TECHNICAL DIRECTIVE PART ONE: STANDARDIZATION AND RELATED ACTIVITIES GENERAL VOCABULARY

SAUDI ARABIAN STANDARDS ORGANIZATION (SASO) TECHNICAL DIRECTIVE PART ONE: STANDARDIZATION AND RELATED ACTIVITIES GENERAL VOCABULARY SAUDI ARABIAN STANDARDS ORGANIZATION (SASO) TECHNICAL DIRECTIVE PART ONE: STANDARDIZATION AND RELATED ACTIVITIES GENERAL VOCABULARY D8-19 7-2005 FOREWORD This Part of SASO s Technical Directives is Adopted

More information

GENEVA COMMITTEE ON DEVELOPMENT AND INTELLECTUAL PROPERTY (CDIP) Fifth Session Geneva, April 26 to 30, 2010

GENEVA COMMITTEE ON DEVELOPMENT AND INTELLECTUAL PROPERTY (CDIP) Fifth Session Geneva, April 26 to 30, 2010 WIPO CDIP/5/7 ORIGINAL: English DATE: February 22, 2010 WORLD INTELLECTUAL PROPERT Y O RGANI ZATION GENEVA E COMMITTEE ON DEVELOPMENT AND INTELLECTUAL PROPERTY (CDIP) Fifth Session Geneva, April 26 to

More information

Doing, supporting and using public health research. The Public Health England strategy for research, development and innovation

Doing, supporting and using public health research. The Public Health England strategy for research, development and innovation Doing, supporting and using public health research The Public Health England strategy for research, development and innovation Draft - for consultation only About Public Health England Public Health England

More information

West Norfolk CCG. CCG 360 o stakeholder survey 2014 Main report. Version 1 Internal Use Only Version 7 Internal Use Only

West Norfolk CCG. CCG 360 o stakeholder survey 2014 Main report. Version 1 Internal Use Only Version 7 Internal Use Only CCG 360 o stakeholder survey 2014 Main report Version 1 Internal Use Only 1 Background and objectives Clinical Commissioning Groups (CCGs) need to have strong relationships with a range of health and care

More information

Staffordshire Police

Staffordshire Police Staffordshire Police ANPR ANPR Project Document Reference: Author: D PLATT Date: 16 TH NOV 2012 Change Control Record Date Document Reference Change By 16/11/12 Initial version, for review D PLATT Contents

More information

COMMISSION RECOMMENDATION. of on access to and preservation of scientific information. {SWD(2012) 221 final} {SWD(2012) 222 final}

COMMISSION RECOMMENDATION. of on access to and preservation of scientific information. {SWD(2012) 221 final} {SWD(2012) 222 final} EUROPEAN COMMISSION Brussels, 17.7.2012 C(2012) 4890 final COMMISSION RECOMMENDATION of 17.7.2012 on access to and preservation of scientific information {SWD(2012) 221 final} {SWD(2012) 222 final} EN

More information

Public Information and Disclosure RD/GD-99.3

Public Information and Disclosure RD/GD-99.3 Public Information and Disclosure RD/GD-99.3 March, 2012 Public Information and Disclosure Regulatory Document RD/GD-99.3 Minister of Public Works and Government Services Canada 2012 Catalogue number CC172-82/2012E-PDF

More information

Review of Technology Level 3 achievement and Level 3 and 4 unit standards. Graphics Design Graphic Communication

Review of Technology Level 3 achievement and Level 3 and 4 unit standards. Graphics Design Graphic Communication Page 1 of 18 Fields Engineering and and Sciences Review of Level 3 achievement and Level 3 and 4 unit standards Unit standards Field Subfield Domain ID Engineering and Design Design Computer 19355 Graphics

More information

Enfield CCG. CCG 360 o stakeholder survey 2015 Main report. Version 1 Internal Use Only Version 1 Internal Use Only

Enfield CCG. CCG 360 o stakeholder survey 2015 Main report. Version 1 Internal Use Only Version 1 Internal Use Only CCG 360 o stakeholder survey 2015 Main report Version 1 Internal Use Only 1 Table of contents Slide 3 Background and objectives Slide 4 Methodology and technical details Slide 6 Interpreting the results

More information

Oxfordshire CCG. CCG 360 o stakeholder survey 2015 Main report. Version 1 Internal Use Only Version 1 Internal Use Only

Oxfordshire CCG. CCG 360 o stakeholder survey 2015 Main report. Version 1 Internal Use Only Version 1 Internal Use Only CCG 360 o stakeholder survey 2015 Main report Version 1 Internal Use Only 1 Table of contents Slide 3 Background and objectives Slide 4 Methodology and technical details Slide 6 Interpreting the results

More information

Southern Derbyshire CCG. CCG 360 o stakeholder survey 2015 Main report. Version 1 Internal Use Only Version 1 Internal Use Only

Southern Derbyshire CCG. CCG 360 o stakeholder survey 2015 Main report. Version 1 Internal Use Only Version 1 Internal Use Only CCG 360 o stakeholder survey 2015 Main report Version 1 Internal Use Only 1 Table of contents Slide 3 Background and objectives Slide 4 Methodology and technical details Slide 6 Interpreting the results

More information

South Devon and Torbay CCG. CCG 360 o stakeholder survey 2015 Main report Version 1 Internal Use Only

South Devon and Torbay CCG. CCG 360 o stakeholder survey 2015 Main report Version 1 Internal Use Only CCG 360 o stakeholder survey 2015 Main report 1 Table of contents Slide 3 Background and objectives Slide 4 Methodology and technical details Slide 6 Interpreting the results Slide 7 Using the results

More information

Economic and Social Council

Economic and Social Council United Nations Economic and Social Council Distr.: General 14 February 2018 Original: English Economic Commission for Europe UNECE Executive Committee Centre for Trade Facilitation and Electronic Business

More information

CCG Assurance and the Balanced Scorecard Balanced Scorecard An overview of the tool, and its role in CCG assurance. Khadir Meer Richard Wells

CCG Assurance and the Balanced Scorecard Balanced Scorecard An overview of the tool, and its role in CCG assurance. Khadir Meer Richard Wells CCG Assurance and the Balanced Scorecard Balanced Scorecard An overview of the tool, and its role in CCG assurance Khadir Meer Richard Wells July 2013 Contents 1. Background: development of the Balanced

More information

Navigating the Healthcare Innovation Cycle

Navigating the Healthcare Innovation Cycle Navigating the Healthcare Innovation Cycle Introduction: CIMIT s 20 + years of experience in facilitating more than 600 projects is that innovation in Healthcare is a learnable, teachable process, which

More information

Years 9 and 10 standard elaborations Australian Curriculum: Design and Technologies

Years 9 and 10 standard elaborations Australian Curriculum: Design and Technologies Purpose The standard elaborations (SEs) provide additional clarity when using the Australian Curriculum achievement standard to make judgments on a five-point scale. They can be used as a tool for: making

More information

TECHNICAL AND OPERATIONAL NOTE ON CHANGE MANAGEMENT OF GAMBLING TECHNICAL SYSTEMS AND APPROVAL OF THE SUBSTANTIAL CHANGES TO CRITICAL COMPONENTS.

TECHNICAL AND OPERATIONAL NOTE ON CHANGE MANAGEMENT OF GAMBLING TECHNICAL SYSTEMS AND APPROVAL OF THE SUBSTANTIAL CHANGES TO CRITICAL COMPONENTS. TECHNICAL AND OPERATIONAL NOTE ON CHANGE MANAGEMENT OF GAMBLING TECHNICAL SYSTEMS AND APPROVAL OF THE SUBSTANTIAL CHANGES TO CRITICAL COMPONENTS. 1. Document objective This note presents a help guide for

More information

THE USE OF A SAFETY CASE APPROACH TO SUPPORT DECISION MAKING IN DESIGN

THE USE OF A SAFETY CASE APPROACH TO SUPPORT DECISION MAKING IN DESIGN THE USE OF A SAFETY CASE APPROACH TO SUPPORT DECISION MAKING IN DESIGN W.A.T. Alder and J. Perkins Binnie Black and Veatch, Redhill, UK In many of the high hazard industries the safety case and safety

More information

Sutton CCG. CCG 360 o stakeholder survey 2015 Main report. Version 1 Internal Use Only Version 1 Internal Use Only

Sutton CCG. CCG 360 o stakeholder survey 2015 Main report. Version 1 Internal Use Only Version 1 Internal Use Only CCG 360 o stakeholder survey 2015 Main report Version 1 Internal Use Only 1 Table of contents Slide 3 Background and objectives Slide 4 Methodology and technical details Slide 6 Interpreting the results

More information

Gloucestershire Clinical Commissioning Group s Effective Clinical Commissioning Policies list Frequently Asked Questions

Gloucestershire Clinical Commissioning Group s Effective Clinical Commissioning Policies list Frequently Asked Questions Gloucestershire Clinical Commissioning Group s Effective Clinical Commissioning Policies list Frequently Asked Questions 1. What is the Effective Clinical Commissioning Policies list? Gloucestershire Clinical

More information

Guide to the Requirements for Public Information and Disclosure GD-99.3

Guide to the Requirements for Public Information and Disclosure GD-99.3 Guide to the Requirements for Public Information and Disclosure GD-99.3 November 2010 Guide to the Requirements for Public Information and Disclosure Guidance Document GD-99.3 Minister of Public Works

More information

Parkinson s World A transformational project by The Cure Parkinson s Trust

Parkinson s World A transformational project by The Cure Parkinson s Trust Parkinson s World A transformational project by The Cure Parkinson s Trust Executive Summary During my time working in the Parkinson s field, I have come to realise there is a patent lack of communication

More information

Social Innovation and new pathways to social changefirst insights from the global mapping

Social Innovation and new pathways to social changefirst insights from the global mapping Social Innovation and new pathways to social changefirst insights from the global mapping Social Innovation2015: Pathways to Social change Vienna, November 18-19, 2015 Prof. Dr. Jürgen Howaldt/Antonius

More information

ENCePP Work Plan

ENCePP Work Plan EMA/150117/2014 ENCePP Secretariat European Network of Centres for Pharmacoepidemiology and Pharmacovigilance European Network of Centres for Pharmacoepidemiology and Pharmacovigilance Adopted by the ENCePP

More information

Assessment element tables

Assessment element tables 1 of 36 20.10.2011 17:13 Assessment element tables The EUnetHTA Joint Action is supported by a grant from the European Commission 1 Health Problem and Current Use of the Technology 2 Description and technical

More information

Decision Determinants Guidance Document

Decision Determinants Guidance Document Decision Determinants Guidance Document The Ontario Health Technology Advisory Committee (OHTAC) Decision-Making Process for the Development of Evidence-Based Recommendations Revised September 2010 Medical

More information

Patient Choice and Resource Allocation Policy. NHS South Warwickshire Clinical Commissioning Group (the CCG)

Patient Choice and Resource Allocation Policy. NHS South Warwickshire Clinical Commissioning Group (the CCG) Patient Choice and Resource Allocation Policy (the CCG) Accountable Director: Alison Walshe Director of Quality and Performance Policy Author: Sheila Browning Associate Director Continuing Healthcare Approved

More information

TECHNOLOGY ENABLED CARE Supporting Service Transformation Delivery Plan 2018/19

TECHNOLOGY ENABLED CARE Supporting Service Transformation Delivery Plan 2018/19 TECHNOLOGY ENABLED CARE Supporting Service Transformation Delivery Plan 2018/19 April 2018 Introduction 1. The TEC Board agreed four Strategic Priorities in August 2017 for furthering the development and

More information

Getting the evidence: Using research in policy making

Getting the evidence: Using research in policy making Getting the evidence: Using research in policy making REPORT BY THE COMPTROLLER AND AUDITOR GENERAL HC 586-I Session 2002-2003: 16 April 2003 LONDON: The Stationery Office 14.00 Two volumes not to be sold

More information

Eco-Schools Curricular Maps - Litter Topic

Eco-Schools Curricular Maps - Litter Topic Eco-Schools Curricular Maps - Litter Topic The series of Outcome Maps in this document suggest how Curriculum for Excellence (CfE) Experiences and Outcomes may be delivered through the Eco-Schools Litter

More information

New Approaches to Safety and Risk Management

New Approaches to Safety and Risk Management New Approaches to Safety and Risk Management 15 18 May 2011 The 3rd DIA China Annual Meeting, Bejjin, China Ayman Ayoub MD MSC (med) Safety Surveillance & Risk Management Pfizer Disclaimer The views/opinions

More information

EMA experience with the review of digital technology proposals in medicine development programmes

EMA experience with the review of digital technology proposals in medicine development programmes EMA experience with the review of digital technology proposals in medicine development programmes 3rd Industry Stakeholder Platform on R&D support, 18 May 2018 Francesca Cerreta, Scientific Advice An agency

More information

East Anglia TWO and East Anglia ONE North. Summary and Approach to Site Selection

East Anglia TWO and East Anglia ONE North. Summary and Approach to Site Selection East Anglia TWO and East Anglia ONE North Summary and Approach to Site Selection 1 Introduction ScottishPower Renewables (SPR) has recently concluded work in order to inform our onshore site selection

More information

ISD Scottish Genetics Genealogy Service

ISD Scottish Genetics Genealogy Service ISD Scottish Genetics Genealogy Service Annual Report 2017 Introduction The genetics genealogy team provide a unique service, supplying accurate and comprehensive family history research for patients who

More information

Marie Skłodowska-Curie Actions Individual Fellowships. Cross-cutting issues in MSCA

Marie Skłodowska-Curie Actions Individual Fellowships. Cross-cutting issues in MSCA Marie Skłodowska-Curie Actions Individual Fellowships Cross-cutting issues in MSCA WHAT THE WORK PROGRAMME 2018-2020 SAYS (INTRODUCTION, P.7) Österreichische Forschungsförderungsgesellschaft Sensengasse

More information

MINERVA: IMPROVING THE PRODUCTION OF DIGITAL CULTURAL HERITAGE IN EUROPE. Rossella Caffo - Ministero per i Beni e le Attività Culturali, Italia

MINERVA: IMPROVING THE PRODUCTION OF DIGITAL CULTURAL HERITAGE IN EUROPE. Rossella Caffo - Ministero per i Beni e le Attività Culturali, Italia MINERVA: IMPROVING THE PRODUCTION OF DIGITAL CULTURAL HERITAGE IN EUROPE. Rossella Caffo - Ministero per i Beni e le Attività Culturali, Italia Abstract The MINERVA project is a network of the ministries

More information